Genus Appoints New Financial Adviser and Joint Corporate Broker
The animal genetics company has appointed J.P. Morgan Securities plc as its new Financial Adviser and joint Corporate Broker.
The animal genetics company has appointed J.P. Morgan Securities plc as its new Financial Adviser and joint Corporate Broker.
The animal genetics company has received regulatory approval for its innovative PRRS Resistant Pig product in the US market.
The healthcare company has received notification of a change in major shareholdings.
The healthcare company has received notification of a change in major shareholdings.
The healthcare company has announced details of restricted stock awards granted to an executive, including vesting and sale of shares to cover tax liabilities.
The healthcare company has announced that BlackRock, Inc. has increased its stake in the firm to over 5% of the voting rights.
The healthcare company has appointed a new Chief Financial Officer to succeed the retiring incumbent.
The CEO of this major biotechnology company has exercised stock options and sold a portion of the resulting shares.
The animal genetics company reported a 19% increase in adjusted operating profit, strong cash generation, and strategic progress in key markets. Despite currency headwinds, the outlook remains positive with increased profit expectations for FY25.
The animal genetics company announces the retirement of a Non-Executive Director, who is leaving to take on a new role.